Uncovering The Science Of Covid-19
Intro -- Contents -- Foreword -- About the Editors -- Chapter 1 The Novel SARS-CoV-2: An Overview on its Detection, Prevention and Control -- 1.1. The SARS-CoV-2 Genome Organization and Evolution -- 1.2. Approach to the Diagnosis and Analysis of SARS-CoV-2 Infection -- 1.2.1. Radiological assessment for COVID-19 -- 1.2.2. SARS-CoV-2 diagnostic tests -- 1.2.3. Serologic tests for SARS-CoV-2 infection -- 1.2.4. Alternative approaches to PCR-based assays -- 1.3. Prevention and Control Strategies -- 1.4. Vaccine Development Against COVID-19 -- 1.4.1. SARS-CoV-2 spike protein as target for vaccine development -- 1.5. Anti-SARS-CoV-2 Therapeutic Drugs -- 1.5.1. Drug repurposing -- 1.5.1.1. Remdesivir -- 1.5.1.2. Lopinavir-ritonavir -- 1.5.1.3. Favipiravir and oseltamivir -- 1.5.1.4. Chloroquine and hydroxychloroquine -- 1.5.2. Convalescent plasma therapy -- 1.5.3. Novel drug development: Some examples -- 1.5.4. Indirect therapeutic agents and candidates for COVID-19 -- 1.5.4.1. Corticosteroids -- 1.5.4.2. Tocilizumab and IL-6 inhibitors -- 1.5.4.3. Inhibitors of NLRP3 inflammasome receptor -- 1.5.4.4. Type III interferon lambda -- 1.6. Conclusion -- References -- Chapter 2 Insights into Molecular Evolution and Increased Transmissibility of SARS-CoV-2 -- 2.1. Introduction -- 2.2. Zoonosis and Host Range Expansion of SARS-CoV-2 -- 2.3. Evolution and Transmission of SARS-CoV-2 -- 2.3.1. Enhanced infectivity -- 2.3.2. Recombination efficiency of the viral genome -- 2.3.3. Mutation rate of the viral genome -- 2.3.4. Ability of the virus to survive in harsh environments -- 2.3.5. Easy access to reach susceptible hosts -- 2.4. Conclusion -- Acknowledgments -- References -- Chapter 3 Clinical Features and Management of COVID-19 -- 3.1. Clinical Features -- 3.1.1. Introduction -- 3.1.2. Asymptomatic infection -- 3.1.3. Clinical symptoms..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2022 ©2022 |
|---|---|
| Erschienen: |
Singapore: World Scientific Publishing Company ; 2022 ©2022 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chow, Vincent T K. [VerfasserIn] |
|---|
| Links: |
ebookcentral.proquest.com [lizenzpflichtig] |
|---|
| ISBN: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Description based on publisher supplied metadata and other sources |
|---|
| Umfang: |
1 online resource (309 pages) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1830156845 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1830156845 | ||
| 003 | DE-627 | ||
| 005 | 20230427073130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230102s2022 xx |||||o 00| ||eng c | ||
| 020 | |a 9789811254338 |9 978-981-12-5433-8 | ||
| 035 | |a (DE-627)1830156845 | ||
| 035 | |a (DE-599)KEP082524149 | ||
| 035 | |a (EBC)EBC7132230 | ||
| 035 | |a (EBL)EBL7132230 | ||
| 035 | |a (EBP)082524149 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chow, Vincent T K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Uncovering The Science Of Covid-19 |
| 264 | 1 | |a Singapore |b World Scientific Publishing Company |c 2022 | |
| 264 | 4 | |c ©2022 | |
| 300 | |a 1 online resource (309 pages) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Description based on publisher supplied metadata and other sources | ||
| 520 | |a Intro -- Contents -- Foreword -- About the Editors -- Chapter 1 The Novel SARS-CoV-2: An Overview on its Detection, Prevention and Control -- 1.1. The SARS-CoV-2 Genome Organization and Evolution -- 1.2. Approach to the Diagnosis and Analysis of SARS-CoV-2 Infection -- 1.2.1. Radiological assessment for COVID-19 -- 1.2.2. SARS-CoV-2 diagnostic tests -- 1.2.3. Serologic tests for SARS-CoV-2 infection -- 1.2.4. Alternative approaches to PCR-based assays -- 1.3. Prevention and Control Strategies -- 1.4. Vaccine Development Against COVID-19 -- 1.4.1. SARS-CoV-2 spike protein as target for vaccine development -- 1.5. Anti-SARS-CoV-2 Therapeutic Drugs -- 1.5.1. Drug repurposing -- 1.5.1.1. Remdesivir -- 1.5.1.2. Lopinavir-ritonavir -- 1.5.1.3. Favipiravir and oseltamivir -- 1.5.1.4. Chloroquine and hydroxychloroquine -- 1.5.2. Convalescent plasma therapy -- 1.5.3. Novel drug development: Some examples -- 1.5.4. Indirect therapeutic agents and candidates for COVID-19 -- 1.5.4.1. Corticosteroids -- 1.5.4.2. Tocilizumab and IL-6 inhibitors -- 1.5.4.3. Inhibitors of NLRP3 inflammasome receptor -- 1.5.4.4. Type III interferon lambda -- 1.6. Conclusion -- References -- Chapter 2 Insights into Molecular Evolution and Increased Transmissibility of SARS-CoV-2 -- 2.1. Introduction -- 2.2. Zoonosis and Host Range Expansion of SARS-CoV-2 -- 2.3. Evolution and Transmission of SARS-CoV-2 -- 2.3.1. Enhanced infectivity -- 2.3.2. Recombination efficiency of the viral genome -- 2.3.3. Mutation rate of the viral genome -- 2.3.4. Ability of the virus to survive in harsh environments -- 2.3.5. Easy access to reach susceptible hosts -- 2.4. Conclusion -- Acknowledgments -- References -- Chapter 3 Clinical Features and Management of COVID-19 -- 3.1. Clinical Features -- 3.1.1. Introduction -- 3.1.2. Asymptomatic infection -- 3.1.3. Clinical symptoms. | ||
| 650 | 4 | |a Electronic books | |
| 700 | 1 | |a Lal, Sunil Kumar |e mitwirkender |4 ctb | |
| 776 | 1 | |z 9789811254321 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789811254321 |
| 856 | 4 | 0 | |u https://ebookcentral.proquest.com/lib/kxp/detail.action?docID=7132230 |m X:EBC |x Aggregator |z lizenzpflichtig |
| 912 | |a ZDB-30-PQE | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a ISIL_DE-31 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a BO | ||
| 980 | |2 2018 |1 01 |x DE-31 |b 4241907911 |c 00 |f --%%-- |d --%%-- |e n |j n |k Für registrierte BenutzerInnen ist der Zugriff auch außerhalb der BLB möglich. |y l01 |z 02-01-23 | ||
| 981 | |2 2018 |1 01 |x DE-31 |r https://www.redi-bw.de/start/blbka/EC-proquest/7132230 | ||